Novo Nordisk sues Eli Lilly, alleging misleading GLP-1 advertising

Novo sues Lilly, alleging ‘misleading’ advertising of obesity drugs

The lawsuit follows a cease-and-desist request and argues Lilly is using “deceptive” ads to claim its GLP-1 products are broadly superior to Novo’s medicines. Lilly countered that its campaign is “truthful.”